SARS_CoV_2 mutation literature information.


  SARS-CoV-2 genetic variations associated with COVID-19 pathogenicity.
 PMID: 34870573       2021       Microbial genomics
Introduction: the mutation D614G in the virus spike protein), which tended to be found together, were reported to show significant positive correlations with death, and to be found more frequently in severe cases than mild cases.
Table: D614G


  Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure.
 PMID: 34871297       2021       PloS one
Introduction: One of the first variations that spread vigorously across countries was Asp614Gly at the spike protein, with this mutation showing higher viral loads than the reference virus from Wuhan, China.
Discussion: A Consurf analysis indicated that all the mutations were located in variable regions of the protein except for Asp614Gly.
Discussion: A comparison of surface hydrophobicity of the trimeric spike reference protein with the Asp614Gly mutation over the simulation trajectory indicated surface hydrophobicity changed for both proteins.


  N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry.
 PMID: 34876606       2021       Scientific reports
Conclusion: The results of this study revealed that the single D614G substitution had impacts on the glycosylation of the spike protein and half of the N-glycosylation sequons in the S showed a difference in the distribution of various glycan forms between the S-614D and S-614G variants.
Conclusion: We analyzed the N-glycosylation profiles of the SARS-CoV-2 spike D614G variant and its ancestor protein using advanced EThcD mass spectrometry.
Introduction: from molecular dynamic (MD) studies on the variant sequence and was supported by a recent cryo-EM study of S-


  Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera.
 PMID: 34877393       2021       Genes & diseases
Abstract: Our results showed that, compared to D614G and B.1.1.7 variants, B.1.617 shows enhanced viral entry and membrane fusion, as well as more resistant to antibody neutralization.


  Analysis of the ARTIC Version 3 and Version 4 SARS-CoV-2 Primers and Their Impact on the Detection of the G142D Amino Acid Substitution in the Spike Protein.
 PMID: 34878296       2021       Microbiology spectrum
Introduction: bearing resemblance to previous evolutionary sweeps, including the D614G substitution in 2020, B.1.1.7 (Alpha) last fall and winter, and Delta this spring and summer (GISAID acknowledgment table can be found at doi: https://doi.org/10.1101/2021.09.27.461949).


  Emergence of novel combinations of SARS-CoV-2 spike receptor binding domain variants in Senegal.
 PMID: 34880295       2021       Scientific reports
Introduction: All three of the genomes carrying the L452R/N501Y combination belonged to the A.27 lineage (clade 19B) and did not encode the D614G mutation that predominates most global infections today.
Introduction: In addition to the L452R + N501Y double mutant, a single genome was identified that carried a unique combination of E484K + N501T spike RBD mutations in a B.1 lineage genome (clade 20C) with D614G also present.


  Additional Positive Electric Residues in the Crucial Spike Glycoprotein S Regions of the New SARS-CoV-2 Variants.
 PMID: 34880635       2021       Infection and drug resistance
7Figure: The reference ""wild-type'"" virus B.1 was assumed (with no mutation D614G and other spike protein changes)."
Abstract: The most often observed were positive mutations, especially D614G and E484K, located in the region of S1/S2 junction, and in the receptor-binding domain (RBD), respectively.
Table: D614G


  Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.
 PMID: 34886943       2021       Euro surveillance
Introduction: In contrast to AY.4.2, the B.1.617.2 strain with E484K had a significant reduction in virus neutralisation titres relative to D614G (4.0-fold) and all other Delta strains tested - B.1.617.2 (2.3-fold), AY.4 (2.3-fold), and AY.4.2 (1.7-fold) (p < 0.050 for all comparisons).
Introduction: Relative to the early pandemic strain (D614G), the AY.4.2 virus had a 2.3-fold reduction in median neutralisation titres (median titre: 199 vs 87; p < 0.001) (Figure 2).
Introduction: Relative to the early pandemic strain (D614G), the reduction in the AY.4.2 sub-lineage-associated virus neutralisation (2.3-fold) was not as pronounced as observed for the Beta variant (4.9-fold).


  Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020.
 PMID: 34886945       2021       Euro surveillance
Abstract: By June 2021, all the emerging variants of concern carried the D614G mutation.
Abstract: IntroductionThe SARS-CoV-2 lineages carrying the amino acid change D614G have become the dominant variants in the global COVID-19 pandemic.
Abstract: The rapid spread of the G614 mutant suggests that it may have a transmission advantage over the D614 wildtype.AimOur objective was to estimate the transmission advantage of D614G by integrating phylogenetic and epidemiological analy


  A Multidimensional Cross-Sectional Analysis of Coronavirus Disease 2019 Seroprevalence Among a Police Officer Cohort: The PoliCOV-19 Study.
 PMID: 34888394       2021       Open forum infectious diseases
Result: Antibodies from seropositive individuals demonstrated neutralization activity against D614G up to a dilution of 1:320 (Supplementary Figure D).
Result: Antibody titers of anti-NCP and anti-S antibodies correlated with the dilution titers showing the highest coefficient with dilution of D614G and the lowest coefficient with dilution of B.1.351 (Beta), with P<.001 in all pairs (Supplementary Table F).
Result: Similar to the overall results of neutralization assays, the neutralization capacity of serum against Alpha and Beta variants was poorer than it was against D614G, even with serum demonstrating both >37.5 U/mL COI anti-NCP antibodies and >65 U/mL anti-S antibodies.



Browser Board

 Co-occurred Entities




   Filtrator